MedTrace Logo

Safety and Efficacy Study of MBX-102 in Treatment of Hyperuricemia in Patients With Gout

NCT01336686 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 67

Last updated 2015-04-17

No results posted yet for this study

Summary

The purpose of the study is to evaluate the safety and effectiveness of MBX-102 compared to placebo when given orally once daily for 4 weeks for the treatment of hyperuricemia in patients with gout.

Conditions

  • Hyperuricemia
  • Gout

Interventions

DRUG

Arhalofenate

Arhalofenate 400 mg once daily for 4 weeks

DRUG

Arhalofenate

Arhalofenate 600 mg once daily for 4 weeks

DRUG

Placebo comparator

Matching placebo once daily for 4 weeks

DRUG

Colchicine

0.6 mg colchicine daily for flare prophylaxis

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2011-11-30
Completion
2011-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01336686 on ClinicalTrials.gov